Epigenomics

雜志介紹

Epigenomics雜志介紹

《Epigenomics》是一本以English為主的未開放獲取國際優秀期刊，中文名稱表觀基因組學，本刊主要出版、報道醫學-GENETICS & HEREDITY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為3，最新CiteScore 指數為5.8。

本刊近期中國學者發表的論文主要有：

• Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects

  Author: Huang, Rong; Wu, Yirong; Zou, Zhengyun

• miR-4732-3p prevents lung cancer progression via inhibition of the TBX15/TNFSF11 axis

  Author: Li, Pengfei; Li, Ying; Bai, Shuping; Zhang, Yu; Zhao, Ling

• Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma

  Author: Xie, Tongji; Fan, Guangyu; Huang, Liling; Lou, Ning; Han, Xiaohong; Xing, Puyuan; Shi, Yuankai

• Low-dose 5-aza-2' -deoxycytidine protects against early renal injury by increasing klotho expression

  Author: Zhao, Yanlong; Zeng, Xiaorong; Xu, Xinli; Wang, Wenjing; Xu, Lei; Wu, Yiying; Li, Hang

英文介紹

Epigenomics雜志英文介紹

Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community.

Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.